Research Progress on the Mechanism of Anti-Tumor Immune Response Induced by TTFields

被引:6
作者
Lan, Yue [1 ,2 ,3 ,4 ]
Zhang, Shaomin [2 ,3 ,4 ]
Pan, Yun [5 ]
Wang, Minmin [2 ,3 ,4 ,6 ]
Chen, Guangdi [1 ]
机构
[1] Zhejiang Univ, Dept Publ Hlth, Sch Med, Hangzhou 310027, Peoples R China
[2] Zhejiang Univ, Dept Biomed Engn, Qiushi Acad Adv Studies, Hangzhou 310027, Peoples R China
[3] Zhejiang Univ, Key Lab Biomed Engn, Minist Educ, Hangzhou 310027, Peoples R China
[4] Zhejiang Univ, Zhejiang Prov Key Lab Cardiocerebral Vasc Detect T, Hangzhou 310027, Peoples R China
[5] Zhejiang Univ, Coll Informat Sci & Elect Engn, Hangzhou 310027, Peoples R China
[6] Zhejiang Univ, Binjiang Inst, Hangzhou 310027, Peoples R China
基金
国家重点研发计划;
关键词
tumor treating fields; mechanism of action; anti-tumor immunity; immunotherapy; TUMOR-TREATING FIELDS; RANDOMIZED PHASE-III; GLIOBLASTOMA; TEMOZOLOMIDE; THERAPY; IMMUNOSURVEILLANCE; CHEMOTHERAPY; NOVOTTF-100A; SURVIVAL; TRIAL;
D O I
10.3390/cancers15235642
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Simple Summary Although conventional and emerging treatment modalities have improved the survival outcomes of cancer patients to some extent, the prognosis for solid tumors remains notably grim. Tumor treating fields, as a novel approach for cancer therapy, have shown promising effects as both a monotherapy and in combination with chemotherapy. However, the underlying mechanisms through which TTFields exert their anticancer effects remain incompletely understood. In recent years, many researchers have suggested that inducing anti-tumor immune responses may be one of the key mechanisms of the anticancer activity of TTFields. Several clinical trials are currently exploring the combination of TTFields with tumor immunotherapy and have achieved positive results. This article reviews the research progress on the mechanisms of TTFields-induced anti-tumor immune responses and discusses their clinical significance. The objective is to offer a streamlined and precise summary to facilitate the future exploration and advancement of TTFields.Abstract Tumor treating fields (TTFields), a biophysical therapy technology that uses alternating electric fields to inhibit tumor proliferation, has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of newly diagnosed or recurrent glioblastomas (GBM) and malignant pleural mesotheliomas (MPM). Clinical trials have confirmed that TTFields are effective in slowing the tumor growth and prolonging patient survival. In recent years, many researchers have found that TTFields can induce anti-tumor immune responses, and their main mechanisms include upregulating the infiltration ratio and function of immune cells, inducing the immunogenic cell death of tumor cells, modulating immune-related signaling pathways, and upregulating the expression of immune checkpoints. Treatment regimens combining TTFields with tumor immunotherapy are emerging as a promising therapeutic approach in clinical practice. Given the increasing number of recently published studies on this topic, we provide an updated review of the mechanisms and clinical implications of TTFields in inducing anti-tumor immune responses. This review not only has important reference value for an in-depth study of the anticancer mechanism of TTFields but also provides insights into the future clinical application of TTFields.
引用
收藏
页数:12
相关论文
共 59 条
[1]   Permeabilizing Cell Membranes with Electric Fields [J].
Aguilar, Alondra A. ;
Ho, Michelle C. ;
Chang, Edwin ;
Carlson, Kristen W. ;
Natarajan, Arutselvan ;
Marciano, Tal ;
Bomzon, Ze'ev ;
Patel, Chirag B. .
CANCERS, 2021, 13 (09)
[2]   Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy [J].
Apetoh, Lionel ;
Ghiringhelli, Francois ;
Tesniere, Antoine ;
Obeid, Michel ;
Ortiz, Carla ;
Criollo, Alfredo ;
Mignot, Gregoire ;
Maiuri, M. Chiara ;
Ullrich, Evelyn ;
Saulnier, Patrick ;
Yang, Huan ;
Amigorena, Sebastian ;
Ryffel, Bernard ;
Barrat, Franck J. ;
Saftig, Paul ;
Levi, Francis ;
Lidereau, Rosette ;
Nogues, Catherine ;
Mira, Jean-Paul ;
Chompret, Agnes ;
Joulin, Virginie ;
Clavel-Chapelon, Francoise ;
Bourhis, Jean ;
Andre, Fabrice ;
Delaloge, Suzette ;
Tursz, Thomas ;
Kroemer, Guido ;
Zitvogel, Laurence .
NATURE MEDICINE, 2007, 13 (09) :1050-1059
[3]   Tumor Treating Fields (TTFields) Concomitant with Immune Checkpoint Inhibitors Are Therapeutically Effective in Non-Small Cell Lung Cancer (NSCLC) In Vivo Model [J].
Barsheshet, Yiftah ;
Voloshin, Tali ;
Brant, Boris ;
Cohen, Gadi ;
Koren, Lilach ;
Blatt, Roni ;
Cahal, Shay ;
Khalil, Tharwat Haj ;
Tov, Efrat Zemer ;
Paz, Rom ;
Klein-Goldberg, Anat ;
Tempel-Brami, Catherine ;
Jacobovitch, Sara ;
Volodin, Alexandra ;
Kan, Tal ;
Koltun, Bella ;
David, Cfir ;
Haber, Adi ;
Giladi, Moshe ;
Weinberg, Uri ;
Palti, Yoram .
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2022, 23 (22)
[4]   RhoA as a Key Regulator of Innate and Adaptive Immunity [J].
Bros, Matthias ;
Haas, Katharina ;
Moll, Lorna ;
Grabbe, Stephan .
CELLS, 2019, 8 (07)
[5]   Photodynamic therapy and anti-tumour immunity [J].
Castano, Ana P. ;
Mroz, Pawel ;
Hamblin, Michael R. .
NATURE REVIEWS CANCER, 2006, 6 (07) :535-545
[6]   Tumor Treating Fields dually activate STING and AIM2 inflammasomes to induce adjuvant immunity in glioblastoma [J].
Chen, Dongjiang ;
Le, Son B. ;
Hutchinson, Tarun E. ;
Calinescu, Anda-Alexandra ;
Sebastian, Mathew ;
Jin, Dan ;
Liu, Tianyi ;
Ghiaseddin, Ashley ;
Rahman, Maryam ;
Tran, David D. .
JOURNAL OF CLINICAL INVESTIGATION, 2022, 132 (08)
[7]   The PD-1/PD-Ls pathway and autoimmune diseases [J].
Dai, Suya ;
Jia, Ru ;
Zhang, Xiao ;
Fang, Qiwen ;
Huang, Lijuan .
CELLULAR IMMUNOLOGY, 2014, 290 (01) :72-79
[8]   Tumor treating fields: a new frontier in cancer therapy [J].
Davies, Angela M. ;
Weinberg, Uri ;
Palti, Yoram .
PHARMACEUTICAL SCIENCE TO IMPROVE THE HUMAN CONDITION: PRIX GALIEN USA 2012, 2013, 1291 :86-95
[9]   T Cells Retain Pivotal Antitumoral Functions under Tumor-Treating Electric Fields [J].
Diamant, Gil ;
Goldman, Hadar Simchony ;
Plotnitsky, Lital Gasri ;
Roitman, Marina ;
Shiloach, Tamar ;
Globerson-Levin, Anat ;
Eshhar, Zelig ;
Haim, Oz ;
Pencovich, Niv ;
Grossman, Rachel ;
Ram, Zvi ;
Volovitz, Ilan .
JOURNAL OF IMMUNOLOGY, 2021, 207 (02) :709-719
[10]   Cancer immunoediting: from immunosurveillance to tumor escape [J].
Dunn, GP ;
Bruce, AT ;
Ikeda, H ;
Old, LJ ;
Schreiber, RD .
NATURE IMMUNOLOGY, 2002, 3 (11) :991-998